Cargando…

Historical BCG vaccination combined with drug treatment enhances inhibition of mycobacterial growth ex vivo in human peripheral blood cells

Tuberculosis (TB) is a leading infectious cause of death globally. Drug treatment and vaccination, in particular with Bacillus Calmette-Guérin (BCG), remain the main strategies to control TB. With the emergence of drug resistance, it has been proposed that a combination of TB vaccination with pharma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prabowo, Satria A., Zelmer, Andrea, Stockdale, Lisa, Ojha, Utkarsh, Smith, Steven G., Seifert, Karin, Fletcher, Helen A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425030/ https://www.ncbi.nlm.nih.gov/pubmed/30890730 http://dx.doi.org/10.1038/s41598-019-41008-4

Ejemplares similares

Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells
por: Painter, Hannah, et al.
Publicado: (2020)

RUTI Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a Shift of Monocyte Phenotype in Mice
por: Prabowo, Satria A., et al.
Publicado: (2019)

High monocyte to lymphocyte ratio is associated with impaired protection after subcutaneous administration of BCG in a mouse model of tuberculosis
por: Zelmer, Andrea, et al.
Publicado: (2018)

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis
por: Zelmer, Andrea, et al.
Publicado: (2016)

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
por: Matsumiya, Magali, et al.
Publicado: (2015)

Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth
por: Fletcher, Helen A, et al.
Publicado: (2009)

MYCOBACTERIAL ABSCESSES AFTER BCG VACCINATION
por: Brennan, R, et al.
Publicado: (2019)

In vitro Mycobacterial Growth Inhibition in South Korean Adults With Latent TB Infection
por: Lee, Hyejon, et al.
Publicado: (2019)

HIV, HCMV and mycobacterial antibody levels: a cross‐sectional study in a rural Ugandan cohort
por: Stockdale, Lisa, et al.
Publicado: (2018)

Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization
por: Kewcharoenwong, Chidchamai, et al.
Publicado: (2018)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series
por: Mahdaviani, Seyed Alireza, et al.
Publicado: (2022)

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
por: O’Shea, Matthew K., et al.
Publicado: (2018)

BCG-induced Disseminated Mycobacterial Infection of Skin and Bone in an Otherwise Immunocompetent Child
por: De, Abhishek, et al.
Publicado: (2017)

Reversing BCG-mediated autophagy inhibition and mycobacterial survival to improve vaccine efficacy
por: Gonzalez-Orozco, Maria, et al.
Publicado: (2022)

Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
por: Tanner, Rachel, et al.
Publicado: (2020)

The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010–2014
por: Brennan, Michael J., et al.
Publicado: (2017)

Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes
por: Naranbhai, Vivek, et al.
Publicado: (2015)

The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy
por: Ru, Huanwei, et al.
Publicado: (2017)

Protective Efficacy of BCG Vaccine against Mycobacterium leprae and Non-Tuberculous Mycobacterial Infections
por: Orujyan, Davit, et al.
Publicado: (2022)

Age-Related Immunoreactivity Profiles to Diverse Mycobacterial Antigens in BCG-Vaccinated Chinese Population
por: Yang, Qing-yuan, et al.
Publicado: (2021)

Mycobacterial arthritis as a complication of a Bacille Calmette-Guérin (BCG) vaccination in an immunocompetent child
por: Dérfalvi, B, et al.
Publicado: (2008)

In Vitro, In Vivo and Ex Vivo Models for Peripheral Nerve Injury and Regeneration
por: Li, Andrew, et al.
Publicado: (2022)

Ex vivo Platforms to Study the Primary and Recall Immune Responses to Intracellular Mycobacterial Pathogens and Peptide-Based Vaccines
por: Davis, William C., et al.
Publicado: (2022)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

The HyVac4 Subunit Vaccine Efficiently Boosts BCG-Primed Anti-Mycobacterial Protective Immunity
por: Billeskov, Rolf, et al.
Publicado: (2012)

Engineering new mycobacterial vaccine design for HIV–TB pediatric vaccine vectored by lysine auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2014)

New Recombinant Mycobacterium bovis BCG Expression Vectors: Improving Genetic Control over Mycobacterial Promoters
por: Kanno, Alex I., et al.
Publicado: (2016)

Bacille Calmette Guérin (BCG) and new TB vaccines: Specific, cross-mycobacterial and off-target effects
por: Fritschi, Nora, et al.
Publicado: (2020)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology
por: Larsson, Alex T, et al.
Publicado: (2023)

Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections
por: Mori, Matteo, et al.
Publicado: (2022)

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Anti-mycobacterial activity correlates with altered DNA methylation pattern in immune cells from BCG-vaccinated subjects
por: Verma, Deepti, et al.
Publicado: (2017)

Impact of SIV infection on mycobacterial lipid-reactive T cell responses in Bacillus Calmette-Guérin (BCG) inoculated macaques
por: Walker, Edith M., et al.
Publicado: (2023)

Mycobacterial DNA-binding protein 1 is critical for BCG survival in stressful environments and simultaneously regulates gene expression
por: Shaban, Amina K., et al.
Publicado: (2023)

Mother-to-newborn transmission of mycobacterial L-forms and Vδ2 T-cell response in placentobiome of BCG-vaccinated pregnant women
por: Dimova, T., et al.
Publicado: (2017)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

The mycobacterial DNA-binding protein 1 (MDP1) from Mycobacterium bovis BCG influences various growth characteristics
por: Lewin, Astrid, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ohbm72lnba6v4i21mk5393qvjp